Webinars
During these online education webinars, leading experts explore current treatments and address controversies in various urological subspecialties.
Every week, you will receive current and relevant updates during our webinars. Expect nothing less than highly-informative presentations, courtesy of the European School of Urology, the EAU Sections and the Guidelines Office.
Join the webinars for free and accumulate CME credits. You can watch the webinars by using your PC, tablet or mobile phone.
- You can find recordings of previously-held webinars here.
- The recordings of the live webinars are converted into accredited e-courses from the ESU school. See the overview here.
Upcoming webinars
Imaging and PSA assessment in nmCRPC patients and the treatment consequencesModerator: Presenter(s)
Prof. Steuber, Hamburg (DE)
Prof. Tombal, Brussels (BE) Save the date: Tuesday 15 June 2021
Time: 18.30 – 19.30 Central European Summer Time (CEST) Three pivotal trials, Prosper, Spartan and Aramis, have shown improved cancer control when treating patients with nmCRPC and low PSA doubling time. The definition of the non-metastatic stage is much depending on the sensitivity of the imaging test, rendering the non-metastatic stage as selection criteria weak. In this context, PSA gains a major role as selection criteria for treatment. On the other hand, in CRPC PSA has limitations in treatment monitoring and imaging might be a more reliable tool to decide when treatment needs to be changed. This webinar sheds light into the difficulties encountered with PSA and imaging when treating nmCRPC patients. At a glance: Publication date: 15 June 2021 Date of preparation May 2021 Participation is free! |
Non-neurogenic Female LUTSChair The European association of Urology has recently released a new guideline on Female Non Neurogenic lower urinary tract symptoms. This is a significant expansion to a previous guideline, which was chiefly concerned with incontinence. As a result several new topic at areas have been included and amongst these are Female bladder outlet obstruction and detrusor under activity in women. The webinar will showcase both of these topic areas and presented an evidence based overview of diagnosis and treatment. The speakers are directly from the new guideline panel and have significant clinical expertise in functional urology. At a glance Participation is free!
|
Developments in perioperative immunotherapy for bladder and kidney cancersChair Programme: Latest developments and future directions of perioperative immunotherapy in bladder cancer Old paradigms and next destinations of perioperative immune-checkpoint inhibition in kidney cancer Clinical case-series: Perioperative treatment with immune-checkpoint inhibitors in bladder and renal cancer Recent developments in the use of immune-checkpoint inhibitors for the treatment of urologic malignancies, primarily for bladder and kidney cancers, provided healthcare providers and physician scientists with a significant momentum resulting in a number of newer therapeutic indications and clinical trials in the field. As such, this wave of therapeutic development is currently addressed to the multidisciplinary treatment of localized disease, i.e. at clinical stages that conventionally define the disease as amenable to radical resection. In addition to the noteworthy developments of immunotherapy strategies into the preoperative setting, most recent data from large clinical trials has revitalized the role of postoperative, adjuvant immunotherapy in bladder and kidney cancers, potentially setting new therapeutic indications in these tumours. In brief, the aims of the course will be the following:
At a glance Participation is free!
|
Understanding the tumor micro-environment in urological cancers to improve immuno-therapyModerators At a glance Participation is free!
|
